Vivus Expectations Drop Its Shares
Vivus Inc.’s (US: vvus) expectations on Friday suddenly let it shares down by 12%, a recent report has uncovered. It had expressed estimations that European regulators might recommend that its Qsymia drug should not be approved by the US Food and Drug Administration.
However, shares of other firms either manufacturing or selling this drug became active in the preopen. Besides, the same brought a rise by 3.2% in the shares of Vivus’s rival Arena Pharmaceuticals Inc. (US: arna). The drug meant for prescription weight loss is now available to certified pharmacies for sales.
Vivus Pharmaceuticals says that Qsymia pronounced as kyoo-SIM-ee-uh is the first ever drug helping in weight loss. And development of the same has taken almost 13 years. While another drug named Belviq was approved by the FDA earlier, Qsymia received its approval last July after Belviq. It has been found that Belviq would be reaching the market by early 2013.
On the other hand, Manhattan MedicalWeight Loss Physician Sue Decotiis, MD says that lifestyle changes alone can also help. Nonetheless, as per the findings, Qsymia helps in weight reduction by some 11% to 14% with side effects like birth defects if consumed during pregnancy. Also, increased heart rate and serious eye problems are amid other problems.